Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Visentin

Showing results (171-180 of 193) with videos related to

Pageof 20
Sort By:
Hemasphere|April 10, 2023
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana LinfomiManuel Gotti, Roberta Sciarra, Alessandro Pulsoni, et al.
Blood Cancer Journal|September 17, 2020
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximabMassimo Gentile, Enrica Antonia Martino, Andrea Visentin, et al.
Blood|January 4, 2019
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impactPanagiotis Baliakas, Sabine Jeromin, Michalis Iskas, et al.
Blood Advances|April 16, 2025
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohortAndrea Serafin, Alessandro Cellini, Enrica Antonia Martino, et al.
Hemasphere|February 18, 2026
Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformationChiara Cosentino, Samir Mouhssine, Antonella Zucchetto, et al.
American Journal of Hematology|February 13, 2021
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL studyFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
American Journal of Hematology|April 20, 2021
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trialsFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
Haematologica|January 12, 2023
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS studyFrancesca R Mauro, Irene Della Starza, Monica Messina, et al.
European Journal of Haematology|December 30, 2020
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
American Journal of Hematology|May 14, 2021
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, et al.
Pageof 20

Showing results (171-180 of 193) with videos related to

Sort By:
Pageof 20
Hemasphere|April 10, 2023
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana LinfomiManuel Gotti, Roberta Sciarra, Alessandro Pulsoni, et al.
Blood Cancer Journal|September 17, 2020
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximabMassimo Gentile, Enrica Antonia Martino, Andrea Visentin, et al.
Blood|January 4, 2019
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impactPanagiotis Baliakas, Sabine Jeromin, Michalis Iskas, et al.
Blood Advances|April 16, 2025
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohortAndrea Serafin, Alessandro Cellini, Enrica Antonia Martino, et al.
Hemasphere|February 18, 2026
Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformationChiara Cosentino, Samir Mouhssine, Antonella Zucchetto, et al.
American Journal of Hematology|February 13, 2021
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL studyFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
American Journal of Hematology|April 20, 2021
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trialsFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
Haematologica|January 12, 2023
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS studyFrancesca R Mauro, Irene Della Starza, Monica Messina, et al.
European Journal of Haematology|December 30, 2020
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
American Journal of Hematology|May 14, 2021
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, et al.
Pageof 20